Literature DB >> 29344476

Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy.

Chau M Pham1, Krishna Kalyam1, Bradley T Smith2, Justin Floyd3, John B Holds4.   

Abstract

Management of nonmetastatic uveal melanoma has been well studied and a large body of work has been published by the Collaborative Ocular Melanoma Study (amongst many others). Management of uveal melanoma that is found to be metastatic upon initial diagnosis, however, is less well defined. We report an interesting case of acute angle closure caused by necrosis and hemorrhage into a large uveal melanoma occurring shortly after initiation of immunomodulatory therapy with ipilimumab and nivolumab for metastatic disease. The use of these immunomodulatory agents in the setting of metastatic uveal melanoma is not well studied, and our case illustrates the importance of interdisciplinary communication in order to best decide the timing of surgical and systemic medical management to optimize outcomes and minimize morbidity.

Entities:  

Keywords:  Acute angle closure; Hemorrhage; Immunomodulatory therapy; Tumor necrosis; Uveal melanoma

Year:  2017        PMID: 29344476      PMCID: PMC5757549          DOI: 10.1159/000460255

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  17 in total

1.  The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma.

Authors:  Justin C Moser; Jose S Pulido; Roxana S Dronca; Robert R McWilliams; Svetomir N Markovic; Aaron S Mansfield
Journal:  Melanoma Res       Date:  2015-02       Impact factor: 3.599

2.  Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Authors:  Riccardo Danielli; Ruggero Ridolfi; Vanna Chiarion-Sileni; Paola Queirolo; Alessandro Testori; Ruth Plummer; Monica Boitano; Luana Calabrò; Costanza De Rossi; Anna Maria Di Giacomo; Pier Francesco Ferrucci; Laura Ridolfi; Maresa Altomonte; Clelia Miracco; Angelo Balestrazzi; Michele Maio
Journal:  Cancer Immunol Immunother       Date:  2011-08-11       Impact factor: 6.968

Review 3.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.

Authors:  M Masson Regnault; J Ofaiche; S Boulinguez; E Tournier; P Rochaix; C Paul; L Lamant; N Meyer
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-03       Impact factor: 6.166

6.  Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Authors:  Jeffrey S Weber; Reinhard Dummer; Veerle de Pril; Celeste Lebbé; F Stephen Hodi
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

7.  Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Authors:  Jason J Luke; Margaret K Callahan; Michael A Postow; Emanuela Romano; Nikhil Ramaiya; Mark Bluth; Anita Giobbie-Hurder; Donald P Lawrence; Nageatte Ibrahim; Patrick A Ott; Keith T Flaherty; Ryan J Sullivan; James J Harding; Sandra D'Angelo; Mark Dickson; Gary K Schwartz; Paul B Chapman; Jedd D Wolchok; F Stephen Hodi; Richard D Carvajal
Journal:  Cancer       Date:  2013-08-02       Impact factor: 6.860

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.

Authors:  A Y Bedikian; S S Legha; G Mavligit; C H Carrasco; S Khorana; C Plager; N Papadopoulos; R S Benjamin
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

Review 10.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13
View more
  1 in total

1.  Ocular Melanoma Presenting as Masquerade Syndrome.

Authors:  Sara Simões Macedo; Mónica Teixeira; Andreia Correia; António Novais; Cátia Cabral
Journal:  Eur J Case Rep Intern Med       Date:  2019-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.